NSCLC IO 2022 - Midyear Review

Year in Review

Analysis of Serum Protein Levels for Biomarker-Guided Therapy with Nivolumab with or without Ipilimumab in Patients with Squamous-Cell Lung Cancer: The SWOG Lung-MAP S1400I Trial

Analysis of the changes in blood circulating soluble proteins resulted in identifying potential response biomarkers to immune checkpoint inhibitors in patients with squamous-cell lung cancer. Read More ›

Year in Review

MEDI5752, a Novel PD-1/CTLA-4 Bispecific Checkpoint Inhibitor for Advanced Solid Tumors: First-in-Human Study

NSCLC IO 2022 - Midyear Review

MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor, showed promising antitumor activity and durable clinical benefit and was tolerated at doses 1500 mg. Read More ›

Year in Review

Camrelizumab Combined with Apatinib and Albumin Paclitaxel in Advanced Nonsquamous NSCLC: CAPAP-Lung Phase 2 Study

NSCLC IO 2022 - Midyear Review

Camrelizumab plus albumin paclitaxel and apatinib resulted in promising antitumor activity with an acceptable safety profile for first-line treatment of advanced NSCLC. Read More ›

Year in Review

First-Line Treatment of Metastatic NSCLC with Durvalumab with or without Tremelimumab in Combination with Chemotherapy: AE Management in the POSEIDON Trial

NSCLC IO 2022 - Midyear Review

The safety profile of durvalumab ± tremelimumab plus chemotherapy was manageable, but with more immune-related adverse events observed with durvalumab and tremelimumab. Read More ›

Year in Review

Resistance Biomarkers to PD-1/PD-L1–Targeted Immune Checkpoint Inhibitors: The PIONeeR Trial

NSCLC IO 2022 - Midyear Review

The PIONeeR trial identified 37 biomarkers that could predict resistance to anti–PD-1/PD-L1 therapy before treatment initiation. Read More ›

NSCLC IO 2022 - Midyear Review

Page 3 of 3